Is Rejuran PN or PDRN? Evidence, FDA Status & Seoul Guide

Rejuran is a brand of injectable polynucleotide (PN), not simply another name for PDRN. PN and polydeoxyribonucleotide (PDRN) are related DNA-derived materials, but recent reviews distinguish them by chain length, molecular weight, and proposed behavior; older papers and product labels have often used the terms inconsistently (PMID 40871045). Published cosmetic evidence is encouraging but limited: a systematic review found nine studies involving 219 people and rated them low to moderate quality (PMID 39645667). As of 22 July 2026, our searches of the U.S. FDA's public drug and device approval databases did not identify a Rejuran authorization. That differs from Skinvive by Juvéderm, which has a specific FDA approval for intradermal injection to improve cheek smoothness in adults over 21.

Is Rejuran PN or PDRN?

Rejuran is described in the medical literature as a purified PN product. Calling it “PDRN” is common shorthand, especially in older articles and marketing, but it blurs a useful distinction. PN generally refers to longer, higher-molecular-weight DNA chains that can form a more viscous hydrogel. PDRN generally refers to shorter fragments with lower molecular weight. No universal cutoff has been adopted, and manufacturers do not always publish full molecular-weight distributions, which is one reason the names still overlap in practice.

This distinction matters when discussing how the material might work. PDRN has a published pharmacology involving adenosine A2A-receptor activity and nucleotide salvage pathways, largely studied in wound-healing and regenerative settings (PMID 28491036). It is not sound to copy that entire mechanism onto an injectable PN product. A 2024 review noted that PN is often explained through PDRN pathways even though PN's mechanism in aesthetic use has not been established to the same degree (PMID 39125793).

What does the published evidence show?

The broadest useful summary is the 2025 systematic review. It included nine studies and 219 patients. The studies differed in treatment area, injection technique, schedule, and outcome measurement, and their quality was rated low or moderate. Improvements were reported in measures such as wrinkles, texture, elasticity, and hydration, but the authors called for better trials and standardized protocols (PMID 39645667). That supports a cautious “promising” conclusion, not a guaranteed result or a single proven schedule.

Two small split-face trials help show what has actually been tested:

• A randomized patient- and evaluator-blinded study enrolled 30 people with crow's feet. A purified PN product was compared with a polycaprolactone product; at 12 weeks, the study found no significant difference between the two sides in its main clinical and imaging measures (PMID 31680395).
• A randomized double-blind study enrolled 27 people and compared three PN sessions with non-crosslinked hyaluronic acid on opposite under-eye areas. Overall visual and global-improvement scores were not significantly different. Some elasticity, hydration, roughness, and pore measurements favored PN, and no serious adverse events were reported in that small study (PMID 32248707).

These studies are relevant, but neither establishes how every Rejuran formulation will perform on every facial area. They are small comparisons with short follow-up, not proof of a universal “glass skin” effect.

What is known about side effects and downtime?

Across the studies summarized in the systematic review, reported short-term effects included injection pain, swelling, redness, itching, and occasional bruising. No severe adverse events were reported in the nine included studies, but 219 patients is too small a body of evidence to rule out uncommon complications. Product choice, injection depth, facial anatomy, sterile technique, medical history, and aftercare all matter.

Small raised injection marks may be visible for a while after treatment. Their duration varies with the formulation, dose, area, and technique, so a fixed “back to normal in 12 hours” promise is not reliable. If travel, photography, or an event is planned, discuss a realistic buffer with the treating clinician.

Is Rejuran FDA-approved in the United States?

We could not identify a U.S. FDA authorization for Rejuran in searches performed on 22 July 2026. This is a dated finding from the FDA's public device approval and drug approval databases, not a statement about every country or every future date. A clinic should not use approval of another injectable as if it applied to Rejuran.

Skinvive by Juvéderm is a useful example of why the exact product and indication matter. FDA PMA supplement P110033/S059, decided on 11 May 2023, covers intradermal injection to improve cheek skin smoothness in adults over 21. It is not a blanket approval for every “skin booster,” every body area, or every hyaluronic-acid product (FDA P110033/S059).

How is Rejuran different from Skinvive or a filler?

• Rejuran: a PN injectable. The aesthetic evidence is growing but remains heterogeneous and mostly small.
• Skinvive: a hyaluronic-acid injectable with the specific U.S. FDA indication described above. Its material, evidence package, and regulatory status are different from Rejuran's.
• Volumizing HA fillers: used to change contour or restore volume. A superficial skin-quality treatment and a structural filler do not answer the same anatomical problem.
• Biostimulators such as Sculptra: use a different material and are planned around gradual collagen-related volume or contour goals.

A product category alone does not decide suitability. Texture, hydration, fine lines, volume loss, pigmentation, scarring, and laxity are different findings and may need different plans.

What should you ask before booking Rejuran in Seoul?

• What is the exact product and formulation, and can I see the sealed package and lot details?
• Which concern and facial area are being treated, and what change is realistic for that area?
• Who will perform the injections, and how will facial anatomy affect the plan?
• Why is this session count being proposed? The published literature does not establish one universal protocol.
• What short-term marks are likely, and how much time should I leave before a flight, event, or photography?
• What alternatives fit the same concern, including doing nothing for now?
• What is included in the quoted price, and which costs would be additional?

At consultation, the useful decision is not whether Rejuran is popular. It is whether the diagnosis, product, treatment area, expected benefit, uncertainty, and recovery time make sense together.

FAQ

Is Rejuran PN or PDRN? Medical reviews describe Rejuran as purified PN. PN and PDRN are related DNA-derived materials, but they should not be treated as exact synonyms.

Does Rejuran work? Small clinical studies report improvements in several skin-quality measures, and a systematic review found promising results. The same review rated the nine included studies low or moderate quality and found substantial variation in protocols, so the evidence does not support a guaranteed result.

Is Rejuran FDA-approved? Our search of the U.S. FDA's public approval databases on 22 July 2026 did not identify a Rejuran authorization. Regulatory status outside the United States is a separate question and should be checked for the exact product and market.

How many sessions do I need? There is no single schedule established for every formulation, area, or concern. Published studies use different protocols. A recommendation should explain why its timing and number of sessions fit your case.

Is Rejuran the same as Skinvive? No. Rejuran is a PN product; Skinvive is a hyaluronic-acid injectable with a specific FDA-approved cheek-smoothness indication. They differ in composition, evidence, regulatory status, and treatment planning.

For clinic-specific logistics, see the Rejuran procedure page. If you are comparing PN with HA injectables or a biostimulator, a consultation is where the treatment area, product, alternatives, and travel timing can be reviewed together.

Reviewed by

Medical wording reviewed by Dr. SangYoul Yun, Board-Certified Dermatologist and AAD International Fellow (IFAAD). Evidence and U.S. FDA database status checked on 22 July 2026. This article provides general information and does not predict an individual result.

Sources

1. Kim ST. Comparison of Polynucleotide and Polydeoxyribonucleotide in Dermatology: Molecular Mechanisms and Clinical Perspectives. Pharmaceutics. 2025. PMID 40871045
2. Lampridou S et al. The Effectiveness of Polynucleotides in Esthetic Medicine: A Systematic Review. J Cosmet Dermatol. 2025. PMID 39645667
3. Lee KWA et al. Polynucleotides in Aesthetic Medicine: A Review of Current Practices and Perceived Effectiveness. Int J Mol Sci. 2024. PMID 39125793
4. Squadrito F et al. Pharmacological Activity and Clinical Use of PDRN. Front Pharmacol. 2017. PMID 28491036
5. Jeong GJ et al. Polycaprolactone and polynucleotide fillers for crow's feet: randomized split-face study. J Cosmet Dermatol. 2020. PMID 31680395
6. Lee YJ et al. Polynucleotide and hyaluronic-acid fillers for periocular rejuvenation: randomized split-face trial. J Dermatolog Treat. 2022. PMID 32248707
7. U.S. Food and Drug Administration. Skinvive by Juvéderm, PMA P110033/S059. Decision date 11 May 2023. FDA approval record